Molidustat - Bayer HealthCare Pharmaceuticals

Drug Profile

Molidustat - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-853934; HIF-PH; HIF-PH inhibitor - Bayer; Hypoxia-inducible factor-prolyl hydroxylase inhibitor - Bayer

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antianaemics; Morpholines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 22 Feb 2018 Bayer initiates enrolment in the MIYABI PD phase III trial for Anaemia in Japan (PO) (NCT03418168)
  • 01 Feb 2018 Bayer plans the MIYABI PD phase III trial for Anaemia in Japan , (NCT03418168)
  • 22 Jan 2018 Bayer initiates enrolment in a the MIYABI HD-C phase III trial for Anaemia in Japan (NCT03351166)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top